Tag
A concise, clinician-friendly summary of the 2026 VA/DoD guideline for treating tobacco and nicotine use, focusing on evidence-based pharmacotherapy, counseling, and new recommendations for electronic and smokeless products.
This phase 2 trial demonstrates that varenicline, a partial nAChR agonist, significantly reduces premature ventricular complexes and nonsustained ventricular tachycardia in post-myocardial infarction patients, offering a novel therapeutic t
Nurse-led interventions, especially intensive counseling combined with varenicline or family-based approaches, significantly enhance smoking cessation rates. Brief advice and counseling also improve outcomes over usual care, supporting nurs
This analysis reveals that varenicline is the most effective and safe pharmacotherapy for smoking cessation in individuals with current or past major depressive disorder, outperforming bupropion and nicotine patches with no increased neurop
A randomized clinical trial demonstrates that varenicline, combined with behavioral counseling, markedly improves nicotine vaping cessation rates in youth aged 16-25 who vape daily and do not regularly smoke tobacco.
